Logo
Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome to ShareScene - Talk Shares And Take Stock With Australia's Sharemarket Community - New Here? Click To Register >

973 Pages (Click to Jump) V  « < 227 228 229 230 231 232 233 > »    
 
  
Reply to this topic

AAH, ARANA THERAPEUTICS LIMITED
fastenyourseatbe...
post Posted: Apr 18 2007, 03:09 PM
  Quote Post


Posts: 838
Thanks: 2


Starting to move dont miss out!



--------------------
 
LIVERPOOL
post Posted: Apr 16 2007, 02:23 PM
  Quote Post


Posts: 1,419
Thanks: 5


In reply to: SunRa on Monday 16/04/07 02:14pm

looking good so far!


 
SunRa
post Posted: Apr 16 2007, 02:14 PM
  Quote Post


Posts: 182
Thanks: 3


QUOTE (daves2074 @ Monday 16/04/07 11:10am)

Going out on a limb a bit there with that prediction aren't you Dave? tongue.gif

 
daves2074
post Posted: Apr 16 2007, 11:10 AM
  Quote Post


Posts: 119
Thanks: 5


In reply to: inflamed on Saturday 14/04/07 02:20pm

Breakout from flag today. move above 1.90 could take it anywhere!

 
inflamed
post Posted: Apr 14 2007, 02:20 PM
  Quote Post


Posts: 455
Thanks: 9


QUOTE (inflamed @ Saturday 14/04/07 02:04pm)

Licopid ? LICOPID is produced and distributed by Pharmaceutical Company “PEPTEK” which is located in the Institute of Bioorganic Chemistry of Russian Academy of Science named after M.M.Shemyakin and Ju.A.Ovchinnikov. ???????

could the previous article have gotten peptechUK & peptek.ru mixed up???????


& it goes back to 1995 so think is totally irrelivant

 
inflamed
post Posted: Apr 14 2007, 02:04 PM
  Quote Post


Posts: 455
Thanks: 9


Licopid ? LICOPID is produced and distributed by Pharmaceutical Company “PEPTEK” which is located in the Institute of Bioorganic Chemistry of Russian Academy of Science named after M.M.Shemyakin and Ju.A.Ovchinnikov. ???????

 


inflamed
post Posted: Apr 14 2007, 01:53 PM
  Quote Post


Posts: 455
Thanks: 9


New age Natural Immunomodulator on the US market
Written by Sam Saribekian

Apr 13, 2007 -- /prbuzz/ -- There is a new age Immunomodulator substitute on the US market, it is a natural capsule form food version of Licopid.

Leukomeal is a functional Medical food that very closely resembles a Russian drug except it is completely natural and has no side effects however possesses more benefits due to a higher concentration of probiotic cell wall fragments of various types instead of an isolated molecule like Licopid.

Anecdotally it has shown to improve quality of life for people with a wide variety of chronic degenerative diseases including:
• Hepatitis C
• Heart disease
• Parkinson’s disease
• Cancer
• Diabetes
• Chronic Fatigue Syndrome
• And more

Some of the greatest achievements of Leukomeal include:
Reduced GGT levels in weeks; Reduced Cholesterol; Reduced Triglycerides; increased immune system… Increased levels of glutathione…

By reducing oxidative stress one can achieve a healthy and prolonged life!

This is a description of Licopid.

Although it is not available in the US, Leukomeal is a better alternative without any side effects.
Origin. Licopid is a new semisynthetic drug of natural origin. As an immunomodulator Licopid enhances suppressed immune response or, in contrast, it can suppress autoimmune reaction.

The active ingredient of Licopid was first revealed in Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of Russian Academy of Sciences, and was developed to a drug by collaborative work of the Russian and British researchers and clinicians.

Randomized double-blind clinical trials held in Russia by Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry and the Institute of Immunology in collaboration with British company Peptech (UK) met GCP (Good Clinical Practice) principles and demonstrated the following advantages of Licopid.

Advantages
• Very effective natural immunomodulator
• Simple and convenient application - in tablets
• Licopid can used in combination with antibiotics and anti-viral drugs to reduce their dose without reduction in therapeutic efficacy
• In case of resistance to or side effects of antibiotics and anti-viral drugs Licopid can use alone for therapy of infection
• Reduction in the frequency of exacerbation in chronic diseases improves the quality of patient's life

Properties. Active ingredient: N-Acetylglucosaminyl-(β1→4)-N-acetylmuramyl-alanyl-D-isoglutamine. It represents the main fragment of bacterial cell wall.

Presentation. Tablets containing 1 mg or 10 mg of the active ingredient, 10 tablets per blister.

Mode of action. Licopid increases general resistance against pathogens by activating phagocyte cells (neutrophils and macrophages). These cells ingest and destroy pathogenic microorganisms and at the same time, they secrete cytokines, which affect T - and B - lymphocytes and thus support the development of specific immune response. In case of suppressed haemopoiesis, e.g. caused by of chemotherapy or irradiation, Licopid treatment results in not only qualitative, but also in quantitative changes in non-specific immunity, namely in rapid neutrophils count restoring.

Therapeutic use. Licopid is used in adults for correcting immune reactions as a component of the complex therapy of various diseases associated with reduction of the immune status, including acute and chronic purulent processes and inflammatory diseases; for prevention of infectious complications in post-trauma, - and postoperative period, in oncology during chemo- and radiotherapy; for treatment of tuberculosis, cervical human papilla virus infections, ophthalmic herpes infection, psoriatic erythroderma, classic, pustular and exsudative forms of psoriasis.

Side effects. Contra-indications are unknown. The raise of the body temperature up to 38° С occasionally observed after taking Licopid can not be considered as a serious side effect, but reflects the development of immune reaction.

 
LIVERPOOL
post Posted: Apr 14 2007, 10:56 AM
  Quote Post


Posts: 1,419
Thanks: 5


Here is another broker who likes ptd.

Huntley's Small Cap

MiTeD (pTD) $1.88
reCOMMeNDATiON: BUY
iNDUSTriAl reviewS AND UpDATeS
SpeCUlATive

aprIl 11 2007 • Issue no. 13 smAller compAnies guide 7
F / Y npAt eps %cHg dps Fr.% Yld per
9/04(a) 28.3 20.3 n/a 0.0 0.0 0.0 9.2
9/05(a) 25.7 16.0 -21.2 8.0* 100.0 4.3 11.7
9/06(a) 5.1 3.1 -80.6 0.0 0.0 0.0 60.5
9/07(e) 6.0 3.6 +16.1 0.0 0.0 0.0 52.1
9/08(e) 7.0 4.3 +19.4 0.0 0.0 0.0 43.6

PTD is a biotechnology company generating royalty
income from its patented intellectual property covering
antibody technology. The over stimulation of Tumour
Necrosis Factor (TNF) causes the destruction of healthy
cells and this is a symptom of rheumatoid arthritis.
Johnson & Johnson and Abbott Laboratories are
generating billions of dollars in revenue from the sale of
anti-TNF compounds known as Remicade and Humera.
Abbott and J&J accept the PTD patent position after
an initial dispute resulting in confidential agreements
covering royalty payment. The current $186m cash
balance will be invested in the product pipeline and
strategic acquisitions. This stock is speculative and
seeks earnings growth through the commercialisation of
the next generation of anti-TNF compounds.
exploring private equity options
The sale of Domantis means PTD’s cash position is $186m
whilst its lucrative licensing deal contributes a total of $100-
$130m up to August 2010. With a market capitalisation of
$310m investors are attaching zero value for the portfolio of
compounds under development. Taking a new compound
from laboratory to market takes at least eight years and burns
considerable amounts of cash. PTD’s strategy, like many,
is to realise value through late stage licensing agreements,
generating upfront milestone and royalty payments.


*Special dividend payment on success of Centracor dispute
Recent share price activity has been driven by the prospect
of possible corporate activity. Chairman Mel Bridges said
unsolicited approaches had come from top tier, global and
industry specialised firms. We scratch our heads as to why a
private equity group would be interested in a biotechnology
company. Private equity normally targets high cash flow
businesses which can sustain high debt payments incurred to
leverage a buy out. After speaking with CEO Chiplin we now
understand.
In the US a number of specialist life science funds invest in
listed and unlisted vehicles. The argument goes if the market
is not efficiently pricing an asset there is an opportunity to
generate superior returns. These funds have the financial
resources to make a full bid for PTD and remove it from
the ASX. PTD will shortly begin safety trials of its second
generation anti-TNF compound PN0621. This compound
aims to compete in the very lucrative anti-TNF market which
today generates US$10.2bn in annual revenues. PTD could
be in a position to start a stage two efficacy trial next year.
Assuming successful trial data then the value of PM0621 will
be significantly higher than today’s perceived zero value. This
is an attractive proposition for a life science fund.
Private equity/life science funds aim to acquire a number of
promising technologies to diversify risk. Unlike the shortterm
appetite of the share market their investment horizon is
three to four years. Funds will wait for good phase two data
then package the business up and sell it on the most suitable
exchange, like the US NASDAQ, to maximise returns.
What is the fair value of the business? This is a difficult
question to answer because of the uncertainty of a drug
compound which can either pay big dividends or nothing. In
our last report we calculated a conservative discount to cash
value of $1.60. On reflection this is harsh and adds no value
for PN0621. This compound was developed by Domantis,
led by Greg Winter the founder of TNF antibody research.
With the market forecast to reach $20bn in sales by 2015
boosted by the aging population, even a partially successful
compound could generate significant revenues.
PN0621 has a patent life until at least 2025. The cost of
goods of the PTD’s compound is set to be cheaper because
it is half the size of a traditional antibody. With a potential 10
year patent protection from market launch successful phase
two data would translates to significant value. We add a value
of $100m, 60cps to our $1.60 cash value and upgrade our
accumulate target to $2.20. This gives no control premium.
PTD says it has had five to six potential acquisition
approaches. Citigroup has been appointed to assess each
approach. This process will take six or so months but the
probability is that further corporate

pepTeCH liMiTeD (pTD) $1.88
reCOMMeNDATiON: BUY
iNDUSTriAl reviewS AND UpDATeS
SpeCUlATive COMpANY SeCTiON
*Special dividend payment on success of Centracor dispute
Recent share price activity has been driven by the prospect
of possible corporate activity. Chairman Mel Bridges said
unsolicited approaches had come from top tier, global and
industry specialised firms. We scratch our heads as to why a
private equity group would be interested in a biotechnology
company. Private equity normally targets high cash flow
businesses which can sustain high debt payments incurred to
leverage a buy out. After speaking with CEO Chiplin we now
understand.
In the US a number of specialist life science funds invest in
listed and unlisted vehicles. The argument goes if the market
is not efficiently pricing an asset there is an opportunity to
generate superior returns. These funds have the financial
resources to make a full bid for PTD and remove it from
the ASX. PTD will shortly begin safety trials of its second
generation anti-TNF compound PN0621. This compound
aims to compete in the very lucrative anti-TNF market which
today generates US$10.2bn in annual revenues. PTD could
be in a position to start a stage two efficacy trial next year.
Assuming successful trial data then the value of PM0621 will
be significantly higher than today’s perceived zero value. This
is an attractive proposition for a life science fund.
Private equity/life science funds aim to acquire a number of
promising technologies to diversify risk. Unlike the shortterm
appetite of the share market their investment horizon is
three to four years. Funds will wait for good phase two data
then package the business up and sell it on the most suitable
exchange, like the US NASDAQ, to maximise returns.
What is the fair value of the business? This is a difficult
question to answer because of the uncertainty of a drug
compound which can either pay big dividends or nothing. In
our last report we calculated a conservative discount to cash
value of $1.60. On reflection this is harsh and adds no value
for PN0621. This compound was developed by Domantis,
led by Greg Winter the founder of TNF antibody research.
With the market forecast to reach $20bn in sales by 2015
boosted by the aging population, even a partially successful
compound could generate significant revenues.
PN0621 has a patent life until at least 2025. The cost of
goods of the PTD’s compound is set to be cheaper because
it is half the size of a traditional antibody. With a potential 10
year patent protection from market launch successful phase
two data would translates to significant value. We add a value
of $100m, 60cps to our $1.60 cash value and upgrade our
accumulate target to $2.20. This gives no control premium.
PTD says it has had five to six potential acquisition
approaches. Citigroup has been appointed to assess each
approach. This process will take six or so months but the
probability is that further corporate activity will drive the price
higher.

 
LIVERPOOL
post Posted: Apr 14 2007, 01:31 AM
  Quote Post


Posts: 1,419
Thanks: 5


In reply to: Pephead on Friday 13/04/07 12:18pm

Hi pep,

I'm just going by past trading. Just two weeks before ann. on advisor, there were a few X trades above 100,000 on low volume similar to the last two days.

I'm just hoping good ann. in a couple of weeks.

 
fastenyourseatbe...
post Posted: Apr 13 2007, 01:21 PM
  Quote Post


Posts: 838
Thanks: 2


THis is not a short term trade. Rivkin put subscribers onto this as they know that we are moving into action season. They will sit this out for 12 months and will make a motsa.

The only losers will be the old followers that get frustrated and sell out on the next run up.

Times are a changing just be patient and it will come and as always when you least expect it. TRADING HALT could come sooner than later.



--------------------
 
 


973 Pages (Click to Jump) V  « < 227 228 229 230 231 232 233 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareScene.com, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING